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Abstract
Background: Patient understanding of study information is fundamental to gaining informed consent to take part in a
randomised controlled trial. In order to meet the requirements of research ethics committees, patient information materials
can be long and need to communicate complex messages. There is concern that standard approaches to providing
patient information may deter potential participants from taking part in trials. The Systematic Techniques for Assisting
Recruitment to Trials (MRC-START) research programme aims to test interventions to improve trial recruitment. The aim of
this study was to investigate the effect on recruitment of optimised patient information materials (with improved
readability and ease of comprehension) compared with standard materials. The study was embedded within two primary
care trials involving patients with long-term conditions.
Methods: The Healthlines Study involves two linked trials evaluating a telehealth intervention in patients with depression
(Healthlines Depression) or raised cardiovascular disease risk (Healthlines CVD). We conducted two trials of a recruitment
intervention, embedded within the Healthlines host trials. Patients identified as potentially eligible in each of the Healthlines
trials were randomised to receive either the original patient information materials or optimised versions of these materials.
Primary outcomes were the proportion of participants randomised (Healthlines Depression) and the proportion expressing
interest in taking part (Healthlines CVD).
Results: In Healthlines Depression (n = 1364), 6.3 % of patients receiving the optimised patient information materials were
randomised into the study compared to 4.0 % in those receiving standard materials (OR = 1.63, 95 % CI = 1.00 to 2.67). In
Healthlines CVD (n = 671) 24.0 % of those receiving optimised patient information materials responded positively to the
invitation to participate, compared to 21.9 % in those receiving standard materials (OR = 1.12, 95 % CI = 0.78 to 1.61).
Conclusions: Evidence from these two embedded trials suggests limited benefits of optimised patient information
materials on recruitment rates, which may only be apparent in some patient populations, with no effects on other
outcomes. Further embedded trials are needed to provide a more precise estimate of effect, and to explore further how
effects vary by trial context, intervention, and patient population.
Trial registration: Current Controlled Trials: Healthlines Depression (ISRCTN27508731) on 26 June 2012; and Healthlines CVD
(ISRCTN14172341) on 5 July 2012
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Background
Randomised controlled trials are the ‘gold standard’ for
evaluating health technologies, yet core aspects of trial
methodology are not, in turn, underpinned by evidence. For
example, recruitment is an essential part of almost all trials
and yet it remains problematic, with around half of all trials
failing to recruit to target and within time [1, 2]. However,
little rigorous quantitative research has been conducted that
can inform recruitment. A recent Cochrane review identi-
fied only 45 randomised evaluations of recruitment inter-
ventions that had been embedded in real trials (i.e. where
patients in the host trial are randomised to different recruit-
ment methods in the embedded trial). The review authors
concluded that ‘trialists should include evaluations of their
recruitment strategies within their trials’ (p. 22) [3].
Increasing the evidence base for recruitment
The MRC-START research programme is a Medical Re-
search Council (MRC) funded study, which seeks to increase
the evidence base for recruitment by developing a platform
to encourage the rapid and rigorous testing of recruitment
interventions. This is done by embedding recruitment inter-
ventions in multiple host trials simultaneously. A fuller de-
scription of the MRC-START model and study has been
provided elsewhere [4].
Recruitment of host trials
As part of the MRC-START programme, principal inves-
tigators (PIs) of trials recently funded by the National
Institute of Health Research (NIHR) Health Technology
Assessment Programme or on the Primary Care Re-
search Network portfolio were invited to participate in
MRC-START. Interested trials were selected on the basis
of size (see ‘Sample size’ section) and design (using a re-
cruitment method amenable to the MRC-START inter-
ventions). Host trials were offered access to one of two
interventions: optimised written patient information ma-
terials or multimedia information presented via the
Internet; both intended to improve communication of
trial information to potential participants. This paper re-
ports the findings of the first two trials testing optimised
printed materials.
The host trial – The Healthlines Study
The Healthlines Study was a large primary care re-
search programme consisting of two multicentre trials
that both evaluated the potential clinical and cost-
effectiveness of telephone support and computer-based
self-management compared to usual care alone. The tel-
ehealth intervention was delivered by NHS Direct
health information advisors, trained to provide struc-
tured support following an evidence-based conceptual
model. This included regular telephone support for use
of computerised packages (e.g. computerised cognitive
behavioural therapy software packages) and home moni-
toring (e.g. blood pressure monitoring).
The telehealth intervention was used in separate trials
in two patient populations: those with increased risk of
cardiovascular disease (Healthlines CVD) and those with
depression (Healthlines Depression) [5]. Both Healthlines
trials identified potential participants by carrying out
anonymised, code-based searches of patient records
within general practices. The practice staff then mailed
the patient information sheet and covering letter. Using
such methods, trials in primary care settings can recruit
from many practices, which is an effective method of
reaching a required sample size. However, the proportion
of patients taking part in trials often remains low, which
can extend recruitment schedules, increase costs, and
can raise doubts about the generalisability of research
because of highly selected samples. Patient uptake in
studies involving telehealth interventions may be espe-
cially problematic, with up to a 75 % refusal rate from
those invited to take part in telehealth trials [6]. A recent
systematic review revealed that, across eight studies, ap-
proximately one third of patients refused to take part in
telehealth interventions, with the most common reasons
being lack of interest and/or believing self-monitoring
was not required [7]. Moreover, some patient groups are
particularly difficult to recruit into research, such as
those with depression [8]. An intervention which im-
proves the proportion of invited patients choosing to
participate by providing better information could have
both logistical and scientific benefits, as well as poten-
tially improving the experience of the trial for patients.
Recruitment intervention – optimised written patient
information material
Appropriate information is fundamental to providing
fully informed consent. However, research ethics com-
mittee requirements mean that standard participant in-
formation can be long and complex [9, 10], which may
have a negative impact on patient understanding and
eventual recruitment, particularly where information
sheets are visually unappealing, confusing or raise anx-
iety. Moreover, members of the public and members of
ethics committees often have different views on what is
of concern with regard to a trial and its procedures [11].
Involving consumers in the development of patient in-
formation can more closely match the information with
the needs and concerns of potential participants, result-
ing in higher relevance and readability, without increas-
ing anxiety [12].
In MRC-START, a process involving consumer feed-
back, expertise in writing for patients and graphic design
is used to produce an optimised version of the patient
information materials (patient information sheet and
covering letter) for each host trial. Potential participants
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in the host trial are then randomised to receive standard
or optimised patient information.
Aims
The MRC-START project aims to assess whether im-
provements in the readability and presentation of patient
information materials results in changes in wider out-
comes, specifically the numbers responding to invita-
tions to participate in a trial and the numbers ultimately
randomised.
Methods
The MRC-START optimised patient information mate-
rials were embedded within the Healthlines Depression
and Healthlines CVD trials. The embedded recruitment
intervention involved a change to trial procedures, to as-
sess whether optimised patient information materials
improved the proportion of patients responding posi-
tively to an invitation to take part in each trial and,
within Healthlines Depression only, the proportion actu-
ally randomised.
Development of the recruitment intervention
The process involves optimisation of readability and naviga-
tion of the documents, using expertise and considerable ex-
perience in writing for patients, as well as drawing on
evidence of what works [13] and expertise in information
graphic design. The revisions are then informed by repeated
user testing [14–17], where the ability of patients to locate
and understand key pieces of information is evaluated ob-
jectively through multiple versions. The optimised sheet
covers the same topics as the original, but differs in form (i.e.
appearance, structure and wording) and effectiveness (i.e. the
ability to transmit the required information). For the user
testing, we recruited healthy members of the public, who
had a similar socio-demographic profile (age, education and
occupation) to the likely samples in the Healthlines trials.
We excluded people who had taken part in any healthcare
trial or readability testing in the previous 6 months.
In the user testing, each participant saw only one version
of the information [14, 15]. We conducted three rounds of
user testing, with ten different participants in each round.
We aimed to ensure some variation in participant character-
istics in each round as well as consistency between rounds.
In each round of 10 participants there were: at least 3 of
each gender; no more than 2 higher education graduates; at
least 4 people aged 18–39 years and at least 1 each aged in
their 40s, 50s, 60s and 70–74 years. We also excluded any-
one who had been treated for depression (or heart disease,
as applicable) in the previous 6 months. Participants were
recruited from the participant database held by Luto Re-
search Limited (Leeds, UK), who were commissioned to
undertake the user testing; participants were members of
the public who had come forward for readability testing
studies. They were paid a small fee to compensate them for
their time.
The first round tested the original Healthlines mate-
rials, after which the revised versions were developed.
The second and third rounds tested the revised versions,
with minor changes made to wording and layout in re-
sponse to the findings of each round of testing. In user
testing, each participant first read a version of the pa-
tient information sheet and covering letter and was then
asked to respond to 20 factual questions: 3 related to the
covering letter and 17 to the information sheet. The
questions were drawn from four categories of informa-
tion that would apply to any trial: the nature and pur-
pose of the trial (three questions); the process and
meaning of consent (four questions); trial procedures
(ten questions); safety, efficacy and nature of the tested
intervention (three questions). For each question, partic-
ipants were asked to locate the answer in the letter or
sheet (testing navigation and organisation of the infor-
mation), then give the answer in their own words (test-
ing understanding). The data derived from user testing
is indicative, not definitive, and so no particular scoring
threshold was used for revisions to be required. Prob-
lems locating an answer suggest a need for clearer navi-
gation or structure; problems in understanding suggest a
need for re-wording. The decision to revise the materials
is also influenced by the commentary from the person
who conducted the user testing – this can indicate the
severity of a problem within a document.
The original Healthlines patient information materials
for both trials were 8-page A5 patient information sheets
in booklet form, together with an A4 covering letter
from the general practitioner (GP).
The patient information sheet was designed in accord-
ance with National Research Ethics Service (NRES) guid-
ance and based on materials used in a related earlier
survey. The patient information materials were devel-
oped and revised through discussion amongst the
Healthlines research team, and then reviewed for plain
language by another researcher, external to the Health-
lines team, with relevant expertise.
The new versions of the Healthlines information
sheets evaluated in the embedded trials were presented
as 4-page A4 booklets and were divided into 8 sections
(as compared with 15 sections in the original versions),
with contrasting colour and a larger font used for sec-
tion headings, to aid navigation. The front page con-
tained a ‘bulleted’ list of trial summary information,
logos, a contents list and contact details, which were
jointly intended to aid reader navigation and have visual
appeal. The re-wording of the information sheets in-
cluded greater use of lay terms, short sentences and par-
agraphs. Additionally, the covering letters were revised
by shortening them by around one third, particularly by
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removing content that was replicated in the information
sheets, as well as adding ‘bullets’ for lists and using bold,
lower case text for emphasis. Examples of the original
and revised patient information material and covering
letters used in Healthlines Depression are available as
Additional files 1, 2, 3 and 4. Data on word count and
readability scores [18] can be found in Additional file 5.
The letters were reduced in length by the process, al-
though the patient information sheets were increased.
Readability was maintained or improved in all cases. It
should be noted that word length and readability indices
are presented for illustrative purposes only, as they are
only partial indicators of the difficulty of a document
and changes in these were not the primary focus of the
process.
Description of the Healthlines host trials and the embedded
recruitment trials
Both embedded trials of recruitment interventions were
conducted over a 4-month period (March 2013 to June
2013) towards the end of the Healthlines recruitment win-
dow at the final 3 participating primary care practices in the
Bristol area (from a total of 43 practices involved in Health-
lines). Practices serving populations from a range of inner
city, suburban and rural settings were recruited with the
help of the Primary Care Research Network (now NIHR
Clinical Research Network, http://www.crn.nihr.ac.uk/). For
efficiency we restricted inclusion in the embedded trial to
practices with patient list sizes of 9000 or more, using com-
puter systems compatible with the Healthlines search query
(EMIS-LV, EMIS Web, and TPP SystmOne), and in one of
three clinical commissioning groups in the South West for
which the study had ethical approval. Letters of invitation,
which briefly explained the nature of the study and commit-
ment expected from each practice, were sent to practices
meeting our criteria and identified by the Primary Care Re-
search Network. Interested practices returned an expression
of interest form, which was passed onto researchers to initi-
ate relevant meetings.
Potentially eligible participants were identified from prac-
tice lists. For Healthlines Depression, the eligibility criteria
were aged at least 18 and a confirmed diagnosis of clinical
depression using standardised measures. For Healthlines
CVD, participants were aged 40–74, with 20 % or greater
risk of having a cardiovascular event in the next 10 years
(QRISK2 score [19]) and had to have at least 1 of 3 modifi-
able risk factors (systolic blood pressure of 140 or greater; a
body mass index (BMI) ≥ 30; or current smoker). Additional
inclusion criteria were access to a telephone, the Internet
and having an Email address for personal use. There were
no additional inclusion or exclusion criteria for the embed-
ded trials.
Standard Healthlines procedure was for lists to be
screened by GPs, and for patients with known exclusion
criteria to be removed. A researcher assisted with
searches and then randomised patients to receive either
the original or optimised patient information materials
(using simple randomisation in a 1:1 ratio). Each prac-
tice list was randomised separately following the same
procedure: each patient was assigned a computer-
generated random number using Excel (Microsoft Inc.,
Redmond, WA, USA). The list included an ID number
for each patient, rather than any identifiable information,
thereby reducing the risk of any selection bias on the
part of the researcher conducting the randomisation.
The list was then sorted by random number, with one
half assigned to the optimised patient information mate-
rials and the other half to the original.
Patients were then sent the appropriate allocated in-
formation materials as part of the invitation to partici-
pate in The Healthlines Study. Due to an expectation of
lower recruitment, a reminder letter was mailed out to
non-responders after 2 weeks in Healthlines Depression
(an administrative error meant that all non-responders
were sent the standard letter, regardless of initial alloca-
tion in the embedded trial). No reminder was used in
Healthlines CVD. Patients were blind to the embedded
recruitment trial (i.e. they were not told they were part
of a recruitment trial – see ‘Research ethics approval’),
while researchers knew about the trial, but were blind to
patient allocation.
The patient was requested to respond by returning ei-
ther a valid consent form or a decline form in a pre-
paid, pre-addressed envelope. If a patient did not wish to
participate, they had the option of providing reasons on
the decline form. In order to carry out pre-screening, in-
terested patients in Healthlines Depression were also
asked to complete and return a standardised depression
assessment tool, the Patient Health Questionnaire-9
(PHQ-9) [20]. If the patient returned a consent form, re-
searchers then contacted them to ask further eligibility
screening questions. For Healthlines Depression, those
patients who scored 10 or more on the PHQ-9 were tel-
ephoned and verbally completed another standardised
depression assessment, the Clinical Interview Schedule -
Revised (CIS-R) [21]. Subsequently, all eligible patients
were randomised on a 1:1 ratio to receive either the
Healthlines Depression intervention and usual care, or
usual care alone.
The process for Healthlines CVD was slightly different.
Importantly, the number of patients actually randomised
within each practice was restricted. This was because
practice staff were required to carry out further eligibility
assessments and staff availability was a concern. In par-
ticular, a CVD risk assessment was carried out by staff at
the practice in order to calculate the patient’s QRISK2
score. The assessment involved taking clinical measures
(e.g. blood pressure, weight and height) and collecting
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information that is required to compute a QRISK2 score.
As covered in more detail above, patients with a 10-year
CVD risk of 20 % or greater, as well as one or more
modifiable risk factors (high blood pressure, overweight,
or current smoker) were deemed eligible. Following fur-
ther eligibility screening by the researchers, the first 25
eligible patients to complete this process at each practice
were randomised on a 1:1 basis to the Healthlines CVD
trial.
Outcome measures
For the embedded trial of optimised patient information
materials in Healthlines Depression, the primary out-
come was the proportion of patients randomised. Sec-
ondary outcomes were the proportion of patients who
accepted the offer of invitation to participate, and the
proportion of eligible patients who actively opted out of
the trial (i.e. returned a ‘decline’ form). Although ‘harm’
in this context could include reduced recruitment in the
intervention group, we did not measure other potential
‘harms’ (such as perceptions of increased pressure to
participate in the intervention group).
For the embedded trial of optimised patient informa-
tion materials in Healthlines CVD, the primary outcome
was the proportion of patients who responded positively
to the invitation to participate. This, rather than actual
randomisation, was selected as the primary outcome be-
cause of a cap on recruitment numbers whereby only
the first 25 eligible participants were randomised in each
practice. This upper limit was implemented because of
practice staff availability to carry out these assessments,
and an initial agreement with researchers that 25 patient
assessments would be sufficient to reach target recruit-
ment across participating GP practices. The secondary
outcome in Healthlines CVD was the proportion of eli-
gible patients who actively opted out (i.e. returned a ‘de-
cline’ form).
Sample size
The sample size calculations for the Healthlines host tri-
als are detailed in the original protocol [5].
In the MRC-START programme, recruitment of host
trials is guided by a generic sample size calculation
which suggests a minimum of 400 patients to be
approached in each arm of the host trial (note that this
is the number of patients approached, not the number
randomised which is the basis of standard sample size
calculations). This generic calculation is detailed in the
published protocol paper [4].
Since the embedded trials were planned to take place
in only a subset of all the primary care practices partici-
pating in Healthlines, data from the host trials were
already available on the numbers of potentially eligible
patients identified, responding, and randomised with
which to inform the sample sizes of the embedded stud-
ies. Prior to the embedded trials, approximately 500 and
250 patients per practice were sent invitations to Health-
lines Depression and Healthlines CVD respectively. Of
these, approximately 5 % were randomised in Health-
lines Depression, and 25 % responded positively in
Healthlines CVD. By conducting the embedded trials
within 3 practices, absolute differences of around 6–7 %
in the primary outcomes in both embedded trials would,
therefore, be detectable with 80 % power and 5 % 2-
sided alpha. While the corresponding relative effects,
particularly in Healthlines Depression of a greater than
2-fold increase in randomisation rate may seem implaus-
ible for the intervention under investigation, this was a
pragmatic decision based on the time it took to prepare
and obtain approvals for the optimised information ma-
terials. Indeed, the original intention was to include four
GP practices, but there was a delay in obtaining ethical
approval to implement the optimised patient informa-
tion sheets.
Data analysis
Analyses were conducted in line with a standard statis-
tical plan developed at Barts and the London Pragmatic
Clinical Trials Unit by SE and VM (details available from
the authors). Preliminary graphical and tabular examin-
ation of the data explored baseline comparability of trial
arms and representativeness of the sample in terms of
the overall eligible population. Outcomes were first de-
scribed separately by arm, and then compared using lo-
gistic regression to estimate the between-group odds
ratio (OR) and corresponding 95 % confidence interval
(CI) on the basis of the intention-to-treat principle. A
planned secondary analysis was performed to explore
whether the impact of the intervention was moderated
by gender. This was done by inserting the appropriate
interaction term in the logistic regression models. All
analyses were conducted using Stata version 12.1 (Stata
Corp., College Station, TX, USA). The statistician con-
ducting the analyses remained blind to allocation until
all analyses were completed.
Research ethics approval
The MRC-START programme of embedded trials of re-
cruitment interventions was approved by the NRES Com-
mittee, Yorkshire and the Humber – South Yorkshire
(Reference: 11/YH/0271) on the 5 August 2011.
The Healthlines host trials were approved by the
NRES Committee, South West, Frenchay, Bristol (Refer-
ence: 12/SW/0009). The embedded trials of recruitment
interventions were added later as a substantial amend-
ment, with optimised versions of the patient information
sheets and covering letters submitted for approval
(granted 14 March 2013). As the core information for
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patients was unchanged, but offered in a different for-
mat, approval was given so that participants did not
need to be informed that they were taking part in an
embedded trial of a recruitment intervention. This also
served to avoid bias and the potential of misunderstand-
ing by patients.
Trial registration
The Healthlines trials are registered with Current Con-
trolled Trials: Healthlines Depression ISRCTN27508731
and Healthlines CVD ISRCTN14172341. The embedded
trials of recruitment interventions were added as sub-
studies to the original trial registrations.
Results
Embedded trial of recruitment interventions in
Healthlines Depression
A total of 1364 patients with depression were included
in the analysis (all patients randomised to the embedded
trial, n = 682 per group, see Fig. 1 for the recruitment
flow chart). Comparison of baseline characteristics
showed a similar mean age (both mean 53) and similar
proportions of men (34 % in optimised materials group
and 33 % in the group receiving the original materials –
see Tables 1 and 2).
The proportion randomised in the Healthlines Depres-
sion trial was 43/682 (6.3 %) among those receiving opti-
mised patient information materials and 27/682 (4.0 %)
in the standard patient information group (OR = 1.63,
95 % CI = 1.00 to 2.67, p = 0.05, Table 3).
The proportions responding positively to the invitation to
participate in Healthlines Depression were 126/682 (18.5 %)
among those receiving optimised patient information mate-
rials compared to 106/682 (15.5 %) in the standard patient
information group (OR = 1.13, 95 % CI = 0.93 to 1.64, p =
0.15). The proportions who actively declined to participate
in Healthlines Depression were 217/682 (31.8 %) among
those receiving optimised patient information materials
compared to 224/682 (32.8 %) in the standard patient infor-
mation group (OR = 0.95, 95 % CI = 0.76 to 1.20, p = 0.69).
There was no evidence that the optimised patient informa-
tion materials were differentially effective at achieving ran-
domisation among men and women (Table 4).
Embedded trial of recruitment interventions in
Healthlines CVD
A total of 671 potential participants were included in the
analysis (all participants randomised to embedded trial,
n = 338 in the optimised group, 333 in the original – see
Fig. 1 for the recruitment flow chart). Comparison of
Fig. 1 Recruitment flowchart for Healthlines embedded trials
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baseline characteristics showed a similar mean age (both
mean 67) and similar proportions of men (72.5 % in
optimised materials group and 72.4 % in the group re-
ceiving the original materials).
The proportion responding positively to the invitation to
participate in Healthlines CVD was 81/338 (24.0 %) among
those receiving optimised patient information materials and
73/333 (21.9 %) in the standard patient information group
(OR = 1.12, 95 % CI = 0.78 to 1.61, p = 0.53, Table 5).
The proportions who actively declined the invitation
to participate in Healthlines CVD were 94/338 (27.8 %)
among those receiving optimised patient information
materials compared to 82/333 (24.6 %) in the standard
patient information group (OR = 1.18, 95 % CI = 0.84 to
1.66, p = 0.35). There was no evidence that the opti-
mised patient information materials were differentially
effective at encouraging a positive response among men
and women (Table 6).
Discussion
We tested the effects of optimised patient information
materials on recruitment into two host trials evaluating
a telehealth self-management intervention. In a group of
patients with depression, the overall rates of participa-
tion were low, but receiving the optimised patient infor-
mation materials did result in a small increase in the
proportion randomised. However, the absolute numbers
recruited were small and the lower confidence limit
around the estimate was consistent with no effect. There
was no evidence of effect on patients at risk of cardio-
vascular disease, nor of effects on other outcomes in ei-
ther population.
Limitations
The number of patients invited to participate in Health-
lines Depression exceeded our generic sample size re-
quirements for the embedded trial, but the numbers
approached for Healthlines CVD were lower.
Aligning the work of the host and embedded re-
cruitment trials was identified as important in qualita-
tive work undertaken to develop the MRC-START
programme [22]. However, it is often difficult to
achieve this in practice, especially where recruitment
studies are not embedded from the beginning of the
host trial. The time required to prepare the optimised
materials (approximately 6 weeks) meant that the em-
bedded trials could only be conducted in 3 practices,
rather than the 4 originally planned. Where possible,
embedded trials would be linked to hosts far earlier
in the process, preferably during the bid development,
or around the time of the funding decision. Compro-
mises may be required in cases where alignment is
not possible, but this may be justified given the very
limited evidence base for recruitment at present.
The difficulties of aligning embedded and host tri-
als was illustrated by an error in study procedures.
All participants were successfully randomised to re-
ceive standard or optimised information initially.
However, the reminder letter (used only in the
Healthlines Depression trial) was not randomised
due to an administrative error, and all participants
in Healthlines Depression received the standard re-
minder letter. Our expectation would be that this
would potentially dilute the impact of the interven-
tion, although it is theoretically possible that the
change in materials may have been salient to partic-
ipants and more likely to evoke a response.
The preferred outcome measure for MRC-START in-
terventions is the number randomised to the host trial.
We were unable to test for an effect on the randomisa-
tion rate in Healthlines CVD. This was due to the cap
placed on recruitment in the host trial, necessary for op-
erational reasons. Whilst real-world trials provide the
best context for examining the effectiveness of interven-
tions aimed at improving recruitment, there will inevit-
ably be occasions when decisions about the management
Table 1 Baseline comparability of patients in the Healthlines
Depression Study
Patient characteristic Optimised Standard
Number Percent Number Percent
Total 682 100.0 % 682 100.0 %
Gender
Male 230 33.7 % 228 33.4 %
Female 452 66.3 % 454 66.6 %
Mean age in years (SD) 52.5 (17.2) 52.7 (17.5)
Table 2 Baseline comparability of patients in the Healthlines
CVD Study
Patient characteristic Optimised Standard
Number Percent Number Percent
Total 338 50.4 % 333 49.6 %
Gender
Male 245 50.4 % 241 49.6 %
Female 93 50.3 % 92 49.8 %
Mean age in years (SD) 66.3 (5.6) 66.7 (5.2)
Table 3 Number and proportion of patients randomised to
Healthlines Depression by recruitment intervention
Randomised to
Healthlines Depression
Patient information Total
Standard Optimised
Number (%) Number (%) Number (%)
No 655 (96) 639 (94) 1294 (95)
Yes 27 (4) 43 (6) 70 (5)
Total 682 (100) 682 (100) 1364 (100)
OR = 1.63, 95 % CI = 1.00 to 2.67, p = 0.05
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of the host trial can place limitations on the design and
delivery of the embedded trial.
Our intervention used a defined and published process
to optimise the content and presentation of patient in-
formation sheets. It is important to note that many re-
searchers routinely involve patients in the development
of their information materials, and the impact of the
optimised materials tested here may be lessened where
patients have already had significant involvement, or
where the trial team have significant prior expertise. Our
work with other trials has highlighted significant vari-
ation in this regard. However, it is important to reiterate
that the optimisation process tested here is not the same
as conventional patient involvement in the development
of trial materials. This is especially true in the degree to
which the materials are formally tested for their ability
to impart information.
We assessed a single moderator variable (gender) as
part of our pre-specified analytic plan. Host trials differ
markedly in terms of the baseline characteristics re-
corded, and gender is one variable which will be present
in most data sets and coded similarly. Our use of gender
as a moderator reflects these pragmatic considerations,
rather than being based on a strong theoretical rationale
about the impact of gender on the effects of enhanced
patient information. Other variables (such as socio-
economic status or health literacy) may be more relevant
but are less likely to be consistently recorded.
Interpretation of the findings in the context of the wider
literature
There is limited literature on the effects of modified in-
formation on trial recruitment. In the previously men-
tioned Cochrane review, three studies explored the
impact of supplementary written material on recruit-
ment and found little evidence of benefit. No previous
studies have looked at optimised participant information
materials of the type evaluated in this study [3].
When compared on the same outcome (positive re-
sponse to an invitation to participate in Healthlines)
there was no effect of the optimised PISs in either pa-
tient population. Due to constraints in the host trials, it
was not possible to test effects on rates of randomisation
across both trials, and it is not clear if the modest posi-
tive impact on proportions of patients randomised is
particular to depressed patients. Although patients with
depression have been found to hold positive attitudes to
Table 4 Number and proportion of patients randomised to Healthlines Depression by recruitment intervention and gender
Gender Randomised to
Healthlines Depression
Patient information Total Odds ratio
Standard Optimised
Number (%) Number (%) Number (%)
Male No 220 (96.5) 215 (93.5) 435 (95)
Yes 8 (3.5) 15 (6.5) 23 (5) 1.919
Sub-total 228 230 458 (100)
Female No 435 (95.8) 424 (93.8) 859 (95)
Yes 19 (4.2) 28 (6.2) 47 (5) 1.512
Sub-total 454 452 906 (100)
Total 682 (50) 681 (50) 1363 (100)
Interaction OR = 0.79, 95 % CI = 0.27 to 2.28, p = 0.660
Table 5 Number and proportion of patients accepting the
invitation to participate in Healthlines CVD by recruitment
intervention
Responded positively
to Healthlines CVD
invite
Patient information Total
Standard Optimised
Number (%) Number (%) Number (%)
No 260 (78) 257 (76) 517 (77)
Yes 73 (22) 81 (24) 154 (23)
Total 333 (100) 338 (100) 671 (100)
OR = 1.12, 95 % CI = 0.78 to 1.61, p = 0.53
Table 6 Number and proportion of patients accepting the
invitation to participate in Healthlines CVD by recruitment
intervention and gender
Gender Accepted
invite to
Healthlines
CVD
Patient information Total Odds
ratioStandard Optimised
Number (%) Number (%) Number (%)
Male No 183 (75.9) 188 (76.7) 371 (76.3)
Yes 58 (24.1) 57 (23.3) 115 (23.7) 0.957
Sub-total 241 245 486 (100)
Female No 77 (83.7) 69 (74.2) 146 (78.9)
Yes 15 (16.3) 24 (25.8) 39 (21.1) 1.786
Sub-total 92 93 185 (100)
Total 333 (100) 338 (100) 671 (100)
Interaction OR = 1.87, 95 % CI = 0.81 to 4.30, p = 0.143
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research participation [23], recruitment to depression
trials is notoriously difficult [24, 25]. The effects of de-
pression on concentration, attention and motivation
have been associated with difficulties using written ma-
terials [26]. It is possible these challenges mean that de-
pressed patients are more able to benefit from the
optimisation process, and thus explain the larger inter-
vention effect in this group.
It should also be noted that improvements in patient
randomisation rates are not the only outcome of opti-
mised materials, which may also impact on improved
understanding, enhanced shared decision-making, and
better patient experience. These outcomes are not rou-
tinely measured in trials. They could be tested through
bespoke measures, but this would add a significant logis-
tical overhead to trials, and our discussions have often
indicated that trials are unwilling to add additional mea-
sures. Alternatively, the addition of nested qualitative
work as part of a programme of mixed methods research
might be a suitable approach to further develop our un-
derstanding of the wider impact of optimised patient
materials.
Implications for recruitment practice
If it is assumed that the effect seen in Healthlines De-
pression is robust, the small increase in the rate of re-
cruitment is likely to have fairly limited advantages in
terms of the external validity of the study sample. How-
ever, the demonstrated increase in the rate of recruit-
ment could have significant logistical benefits for a
larger definitive trial, in terms of the number of practices
that would need to be recruited, or the number of invita-
tion letters to be sent. For example, at a 4 % recruitment
rate, recruiting 600 patients to a definitive trial would re-
quire 15,000 invitations, while a recruitment rate of 6 %
requires only 10,000 invitations. Obviously these poten-
tial advantages need to be set against the financial and
opportunity costs of the optimisation process (approxi-
mately £7000 at current rates), but such calculations are
an important part of study planning, and relatively small
benefits in recruitment rates may be attractive to trial
teams in the context of large studies. These logistical
benefits must also be viewed in the context of other po-
tential benefits that are more difficult to quantify, such
as improved understanding and patient satisfaction.
Generalisability
Our study provides evidence about the effects of
optimised patient information materials on trial re-
cruitment in the context of a telehealth intervention
in two patient populations. Further trials are needed
to assess the effect of optimised patient information
materials, to provide a more precise estimate of ef-
fect on recruitment, consider effects on retention
and explore whether effects vary by trial context,
intervention and patient population. The MRC-
START team plan to conduct analyses of the effects
of two recruitment interventions (either optimised
patient information materials or a multimedia deci-
sion aid, by comparison with standard information)
across twelve host trials.
Conclusions
Evidence from these two embedded trials suggests limited
benefits of optimised patient information materials on
randomisation rates, which may only occur in particular
patient populations. Further embedded trials of these ma-
terials are being conducted to both improve the precision
of these findings, and explore how their effects may vary
by different factors: trial context (e.g. primary care or
other settings), intervention (e.g. different types of opti-
misation), and patient populations (including demo-
graphic and clinical characteristics). Findings from this
research will be included in the Cochrane systematic re-
view of interventions to improve recruitment to trials
[27]. A more comprehensive cohort of embedded trials of
recruitment interventions across the trials portfolio could
lead to a rapid development of the evidence base around
recruitment, to make trials more acceptable and accessible
to patients.
Additional files
Additional file 1: Original version of the covering letter for the
Healthlines Depression trial.
Additional file 2: Optimised version of the covering letter for the
Healthlines Depression embedded trial.
Additional file 3: Sample page from the original version of the
participant information booklet (Healthlines Depression trial).
Additional file 4: Sample page from the optimised version of the
participant information booklet (Healthlines Depression embedded trial).
Additional file 5: Healthlines participant information material word
counts and SMOG index readability scores.
Abbreviations
BMI: body mass index; CIS-R: Clinical Interview Schedule - Revised;
CVD: cardiovascular disease; GP: general practitioner; MRC: Medical Research
Council; MRC-START: Systematic Techniques for Assisting Recruitment to
Trials; NIHR: National Institute of Health Research; NRES: National Research
Ethics Service; OR: odds ratio; PI: principal investigator; PHQ-9: Patient Health
Questionnaire-9; QRISK2: cardiovascular disease risk algorithm.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The following are members of The Healthlines Study Group responsible for
the MRC-START in Healthlines embedded trials: Mei-See Man (MSM); Clare
Thomas (CT); Louisa Edwards (LE); Alan A. Montgomery (AAM); and Chris
Salisbury (CS). Other members of the Healthlines research team not directly
involved with the MRC-START sub-study are listed under acknowledgements.
MM was Healthlines programme manager (maternity cover) during trial
recruitment and led the ethics amendment and sub-study registration for
conducting the embedded MRC-START trial within The Healthlines Study. CT
Man et al. Trials  (2015) 16:309 Page 9 of 11
was Healthlines programme manager during the set-up of the Healthlines
trials. LE was the Research Associate and conducted the practice database
searches, randomisation of participants and collected the primary outcome
data. CT and LE collated the data for analysis. AAM was the PI and lead
statistician for the Healthlines trials. CS is the chief investigator for the
Healthlines research programme and has overall responsibility for the design
and implementation of the Healthlines trials. MM, LE, CT, AAM and CS all
commented on a draft of this paper.
The following are members of the MRC-START Group: Peter Bower (PI: PB);
David Collier (DC); Sandra Eldridge (SE); Jonathan Graffy (JG); Adwoa
Hughes-Morley (AHM); Anne Kennedy (AK); Peter Knapp (PK); Vichithranie
Madurasinghe (VM); Jo Rick (JR); Chris Salisbury (CS); Nicola Small (NS);
David Torgerson (DT); and Shaun Treweek (ST). JR, as project manager for the
MRC-START Study, worked with the Healthlines group to develop the embedded
study protocol, data sharing agreement, substantial amendment and embedded
study registration materials. JR drafted this version of the paper based on
reporting guidelines developed by SE and VM. PK led on the methods
and development of the optimised participant information. SE and VM
designed and VM conducted the data analysis, PB led on the discussion
and implications. PB, DC, SE, JG, AK, PK, CS, DT and ST were applicants on
the original MRC-START application. PB, DC, SE, JG, AHM, AK, PK, VM, JR, CS,
NS, DT, and ST all commented on drafts of the paper. All authors read and
approved the final manuscript.
Authors’ information
The Healthlines Study Group
Mei-See Man, School of Social and Community Medicine, University of
Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK
mei-see.man@bristol.ac.uk
Clare Thomas, Centre for Academic Primary Care, NIHR School for Primary
Care Research, School of Social and Community Medicine, University of
Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK
clare.thomas@bristol.ac.uk
Louisa Edwards, Centre for Academic Primary Care, NIHR School for Primary
Care Research, School of Social and Community Medicine, University of
Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK
louisa.edwards@bristol.ac.uk
Alan A Montgomery, Faculty of Medicine and Health Sciences, Queen’s
Medical Centre, Nottingham, NG7 2UH, UK
alan.montgomery@nottingham.ac.uk
Chris Salisbury, Centre for Academic Primary Care, School of Social and
Community Medicine, University of Bristol, 39 Whitely Road, Bristol, BS8
2PS, UK
c.salisbury@bristol.ac.uk
MRC-START Group
Peter Bower (PI), Medical Research Council North West Hub for Trials
Methodology Research, Manchester Academic Health Science Centre, Centre
for Primary Care, University of Manchester, Oxford Road, Manchester, M13
9PL, UK
peter.bower@manchester.ac.uk
David Collier, William Harvey Research Institute, Barts and the London Queen
Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
d.j.collier@qmul.ac.uk
Sandra Eldridge, Blizard Institute, Barts and The London School of Medicine
and Dentistry, 4 Newark Street, London, E1 2AT, UK
s.eldridge@qmul.ac.uk
Jonathan Graffy, Department of Public Health and Primary Care, The Primary
Care Unit, University of Cambridge, Cambridge, CB2 OSR, UK
jpg43@medschl.cam.ac.uk
Adwoa Hughes-Morley, Medical Research Council North West Hub for Trials
Methodology Research, Manchester Academic Health Science Centre, Centre
for Primary Care, University of Manchester, Oxford Road, Manchester, M13
9PL, UK
adwoa.hughes-morley@manchester.ac.uk
Anne Kennedy, NIHR Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) Wessex, Health Sciences, University of
Southampton, Highfield, Southampton, SO17 1BJ, UK
a.kennedy@soton.ac.uk
Peter Knapp, Department of Health Sciences, University of York, University
Road, Heslington, York, YO10 5DD, UK
peter.knapp@york.ac.uk
Vichithranie Madurasinghe, Blizard Institute, Barts and The London School of
Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK
v.madurasinghe@qmul.ac.uk
Jo Rick, National Institute of Health Research (NIHR) School for Primary Care
Research, Manchester Academic Health Science Centre, Centre for Primary
Care, the University of Manchester, Oxford Road, Manchester, M13 9PL, UK
jo.rick@manchester.ac.uk
Chris Salisbury, Centre for Academic Primary Care, School of Social and
Community Medicine, University of Bristol, 39 Whitely Road, Bristol, BS8 2PS, UK
c.salisbury@bristol.ac.uk
Nicola Small, National Institute of Health Research (NIHR) School for Primary
Care Research, Manchester Academic Health Science Centre, Centre for
Primary Care, the University of Manchester, Oxford Road, Manchester, M13
9PL, UK
nicola.small@manchester.ac.uk
David Torgerson, York Trials Unit, Department of Health Sciences, University
of York, University Road, Heslington, York, YO10 5DD, UK
david.torgerson@york.ac.uk
Shaun Treweek, Health Services Research Unit, University of Aberdeen,
Fosterhill, Aberdeen, AB25 2ZD, UK
streweek@mac.com
Acknowledgments
The Healthlines Study research programme was carried out in
partnership with NHS Direct. This programme was funded by the
National Institute of Health Research (NIHR) under its Programme
Grant for Applied Research (RP-PG-0108-10011). Adwoa Hughes-Morley
is funded by the NIHR on a Doctoral Research Fellowship (NIHR DRF
2012051128). The views expressed are those of the authors and not
necessarily those of the NHS, NIHR or Department of Health. In
addition to those listed as authors on this paper, the Healthlines
research programme is led by Alicia O’Cathain, Sandra Hollinghurst,
Shirley Large, John Nicholl, Anne Rogers, Catherine Pope, Lucy Yardley,
Tom Fahey, and Glyn Lewis.
The authors wish to acknowledge the MRC-START Methodology Research
Programme, which funded the embedded trials (MRC-START Grant
Reference: G1002325). The MRC-START has no role in study design; collection,
management, analysis and interpretation of data; writing of the report; or
the decision to submit the report for publication. We would also like to
acknowledge the contribution of Paul Wallace who was an applicant on the
original proposal. Our thanks go to Luto and Making Sense Design who
worked with PK on the optimised patient information, and Judith Hogg and
Ailsa Donnelly from PRIMER (the Primary Care Research in Manchester
Engagement Resource) who contributed patient and public involvement to
the work of the MRC-START Study team. We thank the reviewers of the
article for their helpful suggestions and comments.
Author details
1School of Social and Community Medicine, University of Bristol, Canynge
Hall, 39 Whatley Road, Bristol BS8 2PS, UK. 2National Institute of Health
Research (NIHR) School for Primary Care Research, Manchester Academic
Health Science Centre, Centre for Primary Care, the University of Manchester,
Oxford Road, Manchester M13 9PL, UK. 3Medical Research Council North
West Hub for Trials Methodology Research, Manchester Academic Health
Science Centre, Centre for Primary Care, University of Manchester, Oxford
Road, Manchester M13 9PL, UK.
Received: 24 October 2014 Accepted: 26 June 2015
References
1. McDonald A, Knight R, Campbell M, Entwistle V, Grant A, Cook J, et al. What
influences recruitment to randomised controlled trials? A review of trials
funded by two UK funding agencies. Trials. 2006;7:9.
2. Sully B, Julious S, Nicholl J. A reinvestigation of recruitment to randomised,
controlled, multicenter trials: a review of trials funded by two UK funding
agencies. Trials. 2013;14:166.
3. Treweek S, Lockhart P, PitKethly M, Cook J, Kjeldstrøm M,
Johansen M, et al. Methods to improve recruitment to randomised
controlled trials: Cochrane systematic review and meta-analysis. BMJ Open.
2013;3:e002360.
Man et al. Trials  (2015) 16:309 Page 10 of 11
4. Rick J, Graffy J, Knapp P, Small N, Collier D, Eldridge S, et al.Systematic
Techniques for Assisting Recruitment to Trials (START): study protocol and
preliminary findings on a platform for nesting studies of recruitment
interventions across multiple trials. Trials. 2014;15:407.
5. Thomas C, Man MS, O’Cathain A, Hollinghurst S, Large S,
Edwards L, et al. Effectiveness and cost-effectiveness of a telehealth
intervention to support the management of long-term conditions: study
protocol for two linked randomized controlled trials. Trials. 2014;15(1):36.
6. Subramanian U, Hopp F, Lowery J, Woodbridge P, Smith D. Research in
home-care telemedicine: challenges in patient recruitment. Telemedicine J
E-Health. 2004;10(2):155–61.
7. Gorst S, Armitage C, Brownsell S, Hawley M. Home
telehealth uptake and continued use among heart failure and chronic
obstructive pulmonary disease patients: a systematic review. Ann Behav
Med. 2014;48(3):323–36.
8. Hughes-Morley A, Young B, Waheed W, Small N, Bower P. Factors affecting
recruitment into depression trials: systematic review and meta-synthesis.
J Affect Disord. 2015;172:274–90.
9. Sugerman J, McCrory D, Hubal R. Getting meaningful informed consent
from older adults: a structured literature review of empirical research.
J Am Geriatr Soc. 1998;46:517–24.
10. Cox A, Fallowfield L, Jenkins V. Communication and
informed consent in phase 1 trials: a review of the literature. Support Care
Cancer. 2006;14:303–9.
11. Petrie K, Faasse K, Notman T, O’Carroll R. How distressing is it to participate
in medical research? A calibration study using an everyday events
questionnaire. J Royal Soc Med Short Rep. 2013;1(4):10.
12. Nilsen E, Myrhaug H, Johansen M, Oliver S, Oxman A. Methods of consumer
involvement in developing healthcare policy and research, clinical practice
guidelines and patient information material. Cochrane Database of
Systematic Reviews. 2006. Issue 3. Art. No.:CD004563. doi:004510.001002/
14651858.CD14004563.pub14651852.
13. Raynor T, Dickinson D. Key principles to guide development of consumer
medicine information – content analysis of information design texts. Ann
Pharmacother. 2010;43(4):700–6. doi:10.1345/aph.1341L1522.
14. Knapp P, Raynor D, Silcock J, Parkinson B. Performance-based readability
testing of participant information for a Phase 3 IVF trial. Trials. 2009;10:79.
15. Knapp P, Raynor D, Silcock J, Parkinson B. Performance-based readability
testing of participant materials for a phase I trial: TGN1412. J Med Ethics.
2009;35:573–8.
16. Knapp P, Raynor D, Silcock J, Parkinson B. Can user testing of a clinical trial
patient information sheet make it fit-for-purpose? – a randomised
controlled trial. BMC Med. 2011;9:89.
17. Raynor D, Knapp P, Silcock J, Parkinson B, Feeney K. ‘User-testing’ as a
method for testing the fitness-for-purpose of written medicine information.
Patient Educ Couns. 2011;83:404–10.
18. McLaughlin G. SMOG Grading – a new readability formula. J Read.
1969;12:639–46.
19. Hippisley Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A,
et al. Predicting cardiovascular risk in England and Wales: prospective
derivation and validation of QRISK2. BMJ. 2008;336:1475–82.
20. Kroenke K, Spitzer R, Williams J. The PHQ-9: validity of a brief depression
severity measure. J Gen Intern Med. 2001;16:606–13.
21. Lewis G, Pelosi A, Araya R, Dunn G. Measuring psychiatric disorder in the
community: a standardized assessment for use by lay interviewers. Psychol
Med. 1992;22:465–86.
22. Graffy J, Bower P, Ward E, Wallace P, Delaney B, Kinmonth A, et al.
Trials within trials? Researcher, funder and ethical perspectives on the
practicality and acceptability of nesting trials of recruitment methods in
existing primary care trials. BMC Med Res Methodol. 2010;10:38.
23. Tallon D, Mulligan J, Wiles N, Thomas L, Peters T, Elgie R, et al. Involving
patients with depression in research: survey of patients’ attitudes to
participation. Br J Gen Pract. 2011;61(585):134–41.
24. Hunt C, Shepherd L, Andrews G. Do doctors know best? Comments on a
failed trial. Med J Aust. 2001;174:144–6.
25. Hetherton J, Matheson A, Robson M. Recruitment by GPs during
consultations in a primary care randomized controlled trial comparing
computerized psychological therapy with clinical psychology and routine
GP care: problems and possible solutions. Prim Health Care Res Dev.
2004;5:5–10.
26. Martinez R, Whitfield G, Dafters R, Williams C. Can people read self-help
manuals for depression? A challenge for the stepped care model and book
prescription schemes. Behav Cogn Psychother. 2014;36(1):89–97.
27. Treweek S, Mitchell E, PitKethly M, Cook J, Kjeldstrøm M, Taskila T, Johansen
M, Sullivan F, Wilson S, Jackson C, et al. Strategies to improve recruitment to
randomised controlled trials. Cochrane Database of Systematic Reviews.
2010. Issue 1. Art. No.:MR000013. DOI: 10.1002/14651858.MR000013.pub4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Man et al. Trials  (2015) 16:309 Page 11 of 11
